An irreversible MAO inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Pargyline (hydrochloride)

Item No. 10007852

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-methyl-N-2-propyn-1-yl-benzenemethanamine, monohydrochloride
CAS Number
306-07-0
Synonyms
  • NSC 43798
Molecular Formula
C11H13N • HCl
Formula Weight
195.7
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMSO: 20 mg/mlEthanol: 30 mg/mlPBS (pH 7.2): 5mg/ml
SMILES
CN(CC#C)CC1=CC=CC=C1.Cl
InChi Code
InChI=1S/C11H13N.ClH/c1-3-9-12(2)10-11-7-5-4-6-8-11;/h1,4-8H,9-10H2,2H3;1H
InChi Key
BCXCABRDBBWWGY-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 mg

    $11

    Add

    500 mg

    $38

    Add

    1 g

    $68

    Add

    5 g

    $283

    Add
    Product Description

    Pargyline is an irreversible inhibitor of monoamine oxidase (MAO; Kis = 15 and 1.8 μM for MAO-A and MAO-B, respectively).1 At 10 mg/kg i.v., pargyline induces a moderate decrease of systolic blood pressure in unanaesthetized hypertensive rats but not normotensive WKR or Sprague-Dawley rats.2 The correlation between the fall of blood pressure and the inhibition of brain MAO suggests that the accumulation of amine in brain is responsible for the fall in pressure.3 Reactive oxygen species-mediated monocyte hypertrophy is prevented by pargyline at a concentration of 10 µM.4 Formulations containing pargyline have been used to treat moderate hypertension.4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fowler, C.J., Mantle, T.J., and Tipton, K.F. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem. Pharmacol. 31(22), 3555-3561 (1982).

    2. Fuentes, J.A., Ordaz, A., and Neff, N.H. Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur. J. Pharmacol. 57(1), 21-27 (1979).

    3. Yamori, Y., De Jong, W., Yamabe, H., et al. Effects of L-dopa and inhibitors of decarboxylase and monoamine oxidase on brain noradrenaline leves and blood pressure in spontaneously hypertensive rats. J. Pharm. Pharmacol. 24(9), 690-695 (1972).

    4. Bianchi, P., Pimentel, D.R., Murphy, M.P., et al. A new hypertrophic mechanism of serotonin in cardiac myocytes: Receptor-independent ROS generation. FASEB J. 19(6), 641-643 (2005).

    5. Puig, M., Wakade, A.R., and Kirpekar, S.M. Effect of the sympathetic nervous system of chronic treatment with parglyline and l-DOPA. J. Pharmacol. Exp. Ther. 182(1), 130-134 (1972).